Abbvie to record $4 billion impairment charges on Stemcentrx assets Medical Dialogues Bureau6 Jan 2019 3:30 AM GMTThe drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid...